Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor

Next Previous
Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HLX 26 (Primary) ; Serplulimab (Primary)
  • Indications Liver cancer; Lung cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 04 Feb 2024 Status changed from active, no longer recruiting to completed.
  • 05 Dec 2023 According to a Henlius Biopharmaceuticals media release, results from this study were presented at the European Society for Medical Oncology Asia (ESMO Asia) Congress 2023.
  • 05 Dec 2023 Results ( N=9, Cut of 19 July 2023) presented in a Henlius Biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top